You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
IF Conversion System for High-Bandwidth Multiplexed Sensors Arrays
SBC: ALPHACORE INC Topic: NoneAlphacore will develop an Intermediate Frequency (IF) Conversion System for High-Bandwidth Multiplexed Sensors Arrays for Phase II of NIST's 2018 soliciation for Exploratory Measurement Science Topic 9.04.02.68.The proposing team has already successfully developed and evaluated a prototype board in Phase I.The goal in Phase II is therefore to achieve three primary objectives:1) Optimize the design ...
SBIR Phase II 2019 Department of CommerceNational Institute of Standards and Technology -
Nanomachine Device for Semiconductor Process Control Monitoring
SBC: XALLENT INC. Topic: NoneConventional characterization and test methods are increasingly ineffective when applied to structures less than 100 nanometers, causing challenges across R&D, process control and failure analysis. An increasing number of subtle defects become prominent drivers of failure as device size and operating margins decrease, e.g., processing anomalies in thin gate oxides, substrate problems related to do ...
SBIR Phase I 2019 Department of CommerceNational Institute of Standards and Technology -
Mobile Health Point-of-Care Diagnostics for Tuberculosis
SBC: B & W TEK INC Topic: NIAIDTuberculosisTBkilled an estimatedmillion people in the world inOverof the mortalities associated with this deisease occurred in regions of the world where access to reliable TB testing and other suppotive infrastructure is severely limitedUntil there are pivotal technological innovations in the diagnosis of TB for point of carePOCapplicationthe ambitious goals of the WHO s End TB strategyareductio ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 in the Context of an Influenza Vaccine
SBC: ADJUVANCE TECHNOLOGIES INC. Topic: NIAIDIncreasingly defined vaccines against infectious diseases are better tolerated but less immunogenicrequiring use of an immunological adjuvant for best effectAdjuvance s semi synthetic saponin adjuvant TiterQuilTQLhas shown remarkable efficacy with a variety of antigens with no detectable reactogenicityWhen combined withof the leading vaccines against influenzaFluzoneFluarix and Flublokstriking aug ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A Liposomal Platform for Spontageous, Particleized Presentation of HIV Trimer Immunogens
SBC: POP Biotechnologies Inc. Topic: NIAIDOver one million Americans andmillion people worldwide are infected with HIVmaking it one of the most pressing public health concerns of our timeUnfortunatelythere are no vaccines available and treatment requires lifelong anti retroviral therapiesThis proposal combines two technologies for the development of a vaccine against HIVEnva novel adjuvantspontaneous nanoliposome antigen particleizationSN ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 386: NOVEL ORALLY BIOAVAILABLE PDE-CATENIN INHIBITOR CONCENTRATES IN LUNG FOR CANCER CHEMOPREVENTION
SBC: ADT Pharmaceuticals, LLC Topic: NCIThis application is based on ADT Pharmaceuticalsdiscoveries thatthe cGMP degrading phosphodiesterase isozymephosphodiesteraseAPDEis overexpressed during early stages of tumorigenesisgenetic knockdown of PDEresults in selective apoptosis of tumor cells by activating cGMP PKG signalingandsmall molecule inhibitors of PDEinduce apoptosis by PKG phosphorylation of oncogeniccateninthereby suppressing Tc ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 356: FLUOROGENIC ASSAY PLATFORM FOR CIRCULAR RNA DETECTION
SBC: LUCERNA INC Topic: NCICircular RNAscircRNAsare a novel class of modified RNAs that are an abundant component of the epitranscriptomePutative functions of circRNAsinclude miRNA sequestrationRNA binding protein scaffoldingmRNA trappingand protein translation regulationDeregulation in one or more of these roles has been linked to several types of cancerOne well studied circRNAciRSis believed to act as a miRNAsponge and in ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
SBIR PHASE 1: SCALABLE DIGITAL DELIVERY OF EVIDENCE-BASED TRAINING FOR FAMILY TO MAXIMIZE TREATMENT ADMISSION RATES OF OPIOID USE DISORDER IN LOVED ONES.
SBC: WE THE VILLAGE, INC. Topic: NIDAThe project goal is to develop digital delivery of Community Reinforcement and Family TrainingCRAFTmethodologyan empirical family behavioral intervention to improve outcomes around treatment entryfamily functioning and substance use
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
DEVELOP NEW COMMERCIALLY VIABLE DEVICES, TOOLS, TECHNOLOGIES OR INTEGRATED SYSTEMS FOR DRUG DETECTION AND DEACTIVATION TO DETER OPIOID THEFT IN HOSPITALS.
SBC: B & W TEK INC Topic: NIDAThe Contractorwill use modern technology to develop a fully integratedcommercially viable device for controlled pharmaceutical drug detectiondeactivationand disposal to ensure compliance with DEA regulations and deter opioid theft
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
STING Inhibitor Discovery for Rare and Common Autoimmune Diseases
SBC: DISCOVERYBIOMED, INC. Topic: NIAIDPrincipal Investigators for Small BusinessDiscoveryBioMedIncDBMand Nitor TherapeuticsIncNitorProject Summary Abstract The over arching commercial goal for this Nitor TherapeuticsIncNitorand DiscoveryBioMedIncDBMcollaboration is to discover and validate Stimulator of Interferon Genes orSTINGinhibitor ligands in a novel high throughput screeningHTSand validation based Critical Path of bioassaysAberr ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health